In GISTs, KIT was also targeted directly by miRNA-218 and miRNA-148b-3p, which acted as tumor suppressors and sensitized GIST cells to imatinib therapy (Fan et al., 2014; Wang Y. et al., 2018). The gene discussed is KIT; the disease is gastrointestinal stromal tumor.